BNP Paribas Asset Management’s AstraZeneca AZN Stock Holding History

BNP Paribas Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.41B	Sell	7,536,227 -88,200	-1%	-$16.6M	1.41%	9
2026 Q1	$1.48B	Buy	7,624,427 +7,405,435	+3,382%	+$1.43B	1.72%	7
2025 Q4	$40.3M	Buy	+218,992	New	+$38.4M	0.05%	354
2021 Q4	–	Sell	-5,049	Closed	-$606K	–	921
2021 Q3	$606K	Buy	+5,049	New	+$588K	﹤0.01%	792
2016 Q4	–	Sell	-35,973	Closed	-$2.36M	–	984
2016 Q3	$2.36M	Buy	+35,973	New	+$2.35M	0.02%	676

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Asset Management's AZN Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its AstraZeneca (AZN) stake by 1.2% in Q2 2026, selling an estimated $16.6M and leaving 7,536,227 shares worth $1.41B. The position accounts for 1.41% of the portfolio, ranked #9.

BNP Paribas Asset Management first reported a position in AZN in Q3 2016 and has held it in 5 quarters since. The position peaked at $1.48B in Q1 2026. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

BNP Paribas Asset Management held 7,536,227 shares of AstraZeneca worth $1.41B as of Q2 2026.
BNP Paribas Asset Management sold 88,200 AstraZeneca shares in Q2 2026, an estimated $16.6M.
AstraZeneca made up 1.41% of BNP Paribas Asset Management's portfolio in Q2 2026, its #9 holding.
BNP Paribas Asset Management first reported a position in AstraZeneca in Q3 2016 and has held it in 5 quarters since.
BNP Paribas Asset Management's AstraZeneca position peaked at $1.48B in Q1 2026.
1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.